Andrew J Smith

Dr. Andrew J Smith


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2017 in Journal of Pharmacy Practice
Verified
Journal Article
Closed access
JSJacob D. Sumner
Jacob D. Sumner
BZBrianna Zinser
Brianna Zinser
ASAndrew J Smith
Andrew J Smith
Purpose: To review the evidence on the safety and efficacy of the continued use of dual antiplatelet therapy (DAPT) beyond 12 months after stent placement in patients following an acute coronary syndrome (ACS) event. Summary: Recently, the American College of Cardiology (ACC) and the American Heart Association (AHA) released a focused update on the duration of DAPT in patients with coronary artery disease (CAD). The update makes new recommendations about the duration of DAPT in light of recently performed studies investigating this topic. In regard to patients after an ACS event, the update states it is reasonable to continue DAPT beyond 1 year if these patients are not at a high risk of bleeding and had no overt bleeding while on DAPT. Several trials have been released which aim to provide information about the correct duration of DAPT after an ACS event. Conclusion: Recent trials have shown a benefit of prolonged (beyond 12 months) DAPT in preventing recurrent cardiovascular (CV) events in patients, mostly in patients who have had a previous myocardial infarction (MI). These benefits must be weighed with the elevated risks of bleeding.

1 August 2014 in American Journal of Health-System Pharmacy
Verified
Journal Article
Closed access
JEJudy Eun
Judy Eun
ASAndrew J Smith
Andrew J Smith
A review of published data on the safety and efficacy of colchicine therapy for primary and secondary prevention of pericarditis is presented. Colchicine has been used effectively as an antiinflammatory agent for gout and has shown promise as a treatment for acute and recurrent pericarditis. Several small studies have indicated that colchicine can decrease pericarditis symptom persistence at 72 hours and pericarditis recurrence rates at 18 months compared with conventional therapy (corticosteroids and aspirin or ibuprofen). A review of pooled data from four prospective randomized trials concluded that colchicine is safe and efficacious for the management of acute and recurrent pericarditis, with the results indicating lower rates of the respective primary and secondary endpoints of recurrent disease and symptom persistence in colchicine-treated patients. A separate meta-analysis of five studies found a reduced risk of pericarditis with colchicine use, suggesting that the drug may have clinical utility in both primary and secondary prevention. The accumulated evidence suggests that treatment with colchicine in the context of pericarditis is safe and well tolerated, with gastrointestinal intolerance being the most common adverse event documented in the clinical trials to date. Based on a review of the literature, prevention of recurrent pericarditis with colchicine can be considered a safe and effective option, though some patients have experienced gastrointestinal intolerance. Due to evidence that corticosteroids may potentially exacerbate the risk of relapse, colchicine may be a safer and preferable option.

17 October 2025 in Advances in Rheumatology
Verified
Journal Article
Open access
PDF file
CLCaleb Lautenschlager
Caleb Lautenschlager
ASAshton Stropes
Ashton Stropes
ASAndrew J Smith
Andrew J Smith
MKMaureen E. Knell
Maureen E. Knell
MSMorgan Sperry
Morgan Sperry
Background: Rheumatoid arthritis is a chronic autoimmune disorder characterized by joint destruction and inflammation. Persistent pain is a common symptom, often impacting quality of life, physical function, and mental health. Despite its prevalence, limited guidance exists for managing chronic rheumatoid arthritis-related pain. This systematic review and meta-analysis aimed to evaluate the effectiveness of various analgesic therapies for managing rheumatoid arthritis-related pain symptoms. Methods: A comprehensive search of PubMed, EMBASE, Cochrane, and ClinicalTrials.gov was conducted from database inception through November 7, 2024. Eligible studies included randomized controlled trials and prospective cohorts reporting pain outcomes in adult rheumatoid arthritis patients. Pain score data was stratified by scale (5-point, 10-point, 100-point) and analyzed using a random-effects model. Results: Twenty-six studies covering 52 treatment regimens were included. Etodolac demonstrated significant pain reduction on a 5-point scale (200 mg: 3.24; 95% CI: 2.86 to 3.63; p < 0.001; 300 mg: 3.35; 95% CI: 2.96 to 3.74; p = 0.00). Piroxicam also showed benefit (20 mg: 3.35; 95% CI: 2.91 to 3.78; p < 0.001). On the 10-point scale, only extracorporeal shock wave therapy significantly reduced pain (3.36; 95% CI: 2.25 to 4.48; p < 0.001). Celecoxib (Celbesta) (200 mg BID) was most effective in the 100-point subgroup (1.73; 95% CI: 1.32 to 2.15; p < 0.001). Heterogeneity was high (I² = 91.1%, 94.1%, 60.2%; all p < 0.05), and publication bias was present. Conclusion: Several therapies demonstrated substantial pain relief, but heterogeneity, publication bias, and varying study quality limit generalizability. High-quality, long-term trials with standardized pain assessments are needed to guide personalized rheumatoid arthritis pain management. Clinical trial number: PROSPERO CRD42024593971, 4 October 2024.

23 January 2026 in Pharmacy
Verified
Journal Article
Open access
PDF file
APAbby C. Poage
Abby C. Poage
JRJordan M. Rowe
Jordan M. Rowe
MDMaryBeth A. Dameron
MaryBeth A. Dameron
ABAbigail M. Bavuso
Abigail M. Bavuso
ASAndrew J Smith
Andrew J Smith
This single health system, retrospective cohort study compared subcutaneous (SC) versus intramuscular (IM) estradiol administration in 70 adult patients with a diagnosis of gender incongruence or gender dysphoria seen in an LGBTQ Specialty Clinic within a safety-net institution between October 2018 and December 2024. The primary endpoint was patients who reached therapeutic estradiol levels at 6 months. Secondary endpoints included the incidence of sub- and supra-therapeutic and actual estradiol levels at months 3, 6, 9, and 12 and patients who received pharmacist-led injection technique education. At 6 months, the proportion of patients achieving therapeutic estradiol levels did not differ between IM and SC administration. In exploratory analyses of continuous estradiol concentrations, IM administration was associated with higher measured estradiol levels.